CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: VPS41 (ImmuneEditome ID:27072)

1. Gene summary of enriched editing regions for VPS41

check button Gene summary
Gene informationGene symbol

VPS41

Gene ID

27072

GeneSynonymsHVPS41|HVSP41|SCAR29|hVps41p
GeneCytomap

7p14.1

GeneTypeprotein-coding
GeneDescriptionvacuolar protein sorting-associated protein 41 homolog|S53|VPS41, HOPS complex subunit|vacuolar assembly protein 41|vacuolar protein sorting 41 homolog
GeneModificationdate20230329
UniprotIDP49754;H7BXH3;C9JZ11;C9J3F8;C9JU58;C9J2U9;H7C0K2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr7:38723419-38724913:-ENST00000310301.7ENSG00000006715.14VPS41UTR3AluSx3,MIRb,AluSpchr7:38723419-38724913:-.alignment


Top

2. Tumor-specific enriched editing regions for VPS41


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr7:38723419-38724913:-BRCAEER2.8712e-02image
ENSG00000006715.14,VPS41BRCAEAG3.1758e-02image
chr7:38723419-38724913:-LUSCEER1.6529e-06image
ENSG00000006715.14,VPS41LUSCEAG1.6547e-06image
chr7:38723419-38724913:-PRADEER1.5708e-04image
ENSG00000006715.14,VPS41PRADEAG1.5985e-04image
chr7:38723419-38724913:-UCECEER2.3670e-03image
ENSG00000006715.14,VPS41UCECEAG3.1031e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr7:38723419-38724913:-HNSCCliEER2.6508e-021.4393e-02-0.1144image
ENSG00000006715.14,VPS41HNSCCliEAG2.6508e-021.4393e-02-0.1144image
chr7:38723419-38724913:-KIRCPathEER4.8662e-032.6451e-030.1306image
ENSG00000006715.14,VPS41KIRCPathEAG2.7700e-031.5572e-030.1374image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for VPS41


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr7:38723419-38724913:-LGGEERENSG00000159082,SYNJ1-0.47031.3813e-251.5410e-26-0.4410imageNNSYNJ1Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000040341,STAU2-0.45912.7274e-242.1609e-26-0.4399imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000172915,NBEA-0.44557.5921e-236.3784e-26-0.4361imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000156011,PSD3-0.44467.7175e-232.7567e-22-0.4052imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000164715,LMTK2-0.43782.8618e-227.5132e-23-0.4102imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000197535,MYO5A-0.44032.9652e-221.8121e-23-0.4156imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000007168,PAFAH1B1-0.43381.1295e-211.5928e-25-0.4329imageNNPAFAH1B1Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000065559,MAP2K4-0.43331.5141e-211.2124e-22-0.4084imageNNMAP2K4Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000164830,OXR1-0.43391.7476e-211.9554e-22-0.4066imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-LGGEERENSG00000183826,BTBD9-0.42684.1877e-215.4338e-22-0.4026imageNNBTBD9Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for VPS41


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000006715.14,VPS41
DLBCEAGIRENSG00000168010.6chr1172822321:72822961:72824059:72824122-0.53324.0042e-022.0025e-04-0.5552imageNADAR;AUH;BCCIP;BUD13;CBX7;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000006715.14,VPS41
DLBCEAGIRENSG00000143774.12chr1228145509:228145649:228146025:228146066-0.68342.7322e-022.3544e-06-0.6503imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMast_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000006715.14,VPS41
ESCAEAGESENSG00000198001.9chr1243768102:43768272:43771219:43771365:43772179:437723620.33969.5655e-033.9209e-070.4159imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1IRAK4Mast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr7:38723419-38724913:-
ESCAEERESENSG00000198001.9chr1243768102:43768272:43771219:43771365:43772179:437723620.33898.4297e-033.8661e-070.4161imageNNIRAK4Mast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000006715.14,VPS41
LGGEAGESENSG00000077522.8chr1236725932:236726020:236727677:236727756:236731232:236731314-0.28093.0513e-111.4064e-17-0.4096imageNADAR;CELF2;CNBP;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP2;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;MBNL2;MOV10;NOP56;NOP58;NUMA1;QKI;RANGAP1;RBFOX2;RBM10;SRSF1;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;ZNF184ACTN2Macrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000006715.14,VPS41
LGGEAGESENSG00000197959.9chr1172308727:172308839:172323328:172323340:172379017:172379076-0.28662.3000e-131.2518e-18-0.4032imageNADAR;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LIN28;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NPM1;PCBP2;PTBP1;QKI;RBFOX2;RBM10;RBM5;RBM6;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;UPF1;YTHDC1;ZC3H7B;ZNF184DNM3Macrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000006715.14,VPS41
LGGEAGIRENSG00000125505.12chr1954178142:54178941:54180772:54181133-0.39534.4252e-171.5824e-22-0.4084imageNADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-
LGGEERIRENSG00000125505.12chr1954178142:54178941:54180772:54181133-0.39531.3295e-151.5824e-22-0.4084imageNNNAMacrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr7:38723419-38724913:-
LGGEERMEXENSG00000140416.15chr1563062628:63062645:63064063:63064142:63069869:63070468:63071089:630712220.37323.3146e-153.7823e-210.4009imageNNTPM1Macrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr7:38723419-38724913:-
LGGEERESENSG00000116604.13chr1156475107:156475237:156476493:156476514:156477011:156477093-0.35689.8909e-141.9294e-21-0.4014imageNNMEF2DMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

5. Enriched editing regions and immune infiltration for VPS41


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000006715.14,VPS41ACCEAGMonocytes2.1115e-02-0.2642image
chr7:38723419-38724913:-BLCAEERT_cells_CD4_memory_activated4.8687e-030.1409image
ENSG00000006715.14,VPS41BLCAEAGT_cells_CD4_memory_activated4.4563e-030.1421image
chr7:38723419-38724913:-BRCAEERMast_cells_resting1.5373e-04-0.1158image
ENSG00000006715.14,VPS41BRCAEAGMast_cells_resting6.0623e-05-0.1224image
chr7:38723419-38724913:-CESCEERT_cells_CD4_memory_resting3.2605e-02-0.1236image
ENSG00000006715.14,VPS41CESCEAGT_cells_CD4_memory_resting3.2605e-02-0.1236image
chr7:38723419-38724913:-CHOLEERT_cells_CD4_naive4.9043e-020.3401image
ENSG00000006715.14,VPS41CHOLEAGT_cells_CD4_naive4.9043e-020.3401image
chr7:38723419-38724913:-COADEERDendritic_cells_resting4.5013e-02-0.1242image
ENSG00000006715.14,VPS41DLBCEAGT_cells_follicular_helper1.6149e-02-0.3568image
chr7:38723419-38724913:-ESCAEERMast_cells_activated2.2235e-020.1807image
ENSG00000006715.14,VPS41ESCAEAGMast_cells_activated2.2291e-020.1806image
chr7:38723419-38724913:-GBMEERMacrophages_M01.6378e-02-0.1872image
ENSG00000006715.14,VPS41GBMEAGMacrophages_M01.6378e-02-0.1872image
chr7:38723419-38724913:-HNSCEERT_cells_CD4_memory_activated5.3050e-040.1594image
ENSG00000006715.14,VPS41HNSCEAGT_cells_CD4_memory_activated5.3050e-040.1594image
chr7:38723419-38724913:-KICHEERT_cells_gamma_delta4.1736e-02-0.2533image
ENSG00000006715.14,VPS41KICHEAGT_cells_gamma_delta4.1736e-02-0.2533image
chr7:38723419-38724913:-KIRCEERB_cells_memory2.8104e-020.1122image
ENSG00000006715.14,VPS41KIRCEAGB_cells_memory2.3820e-020.1155image
chr7:38723419-38724913:-KIRPEERT_cells_CD4_memory_resting6.7456e-05-0.2330image
ENSG00000006715.14,VPS41KIRPEAGT_cells_CD4_memory_resting6.7456e-05-0.2330image
chr7:38723419-38724913:-LAMLEERMast_cells_resting4.3134e-02-0.2069image
ENSG00000006715.14,VPS41LAMLEAGMast_cells_resting2.3722e-02-0.2295image
chr7:38723419-38724913:-LGGEERMacrophages_M22.1705e-050.1837image
ENSG00000006715.14,VPS41LGGEAGMacrophages_M22.1705e-050.1837image
chr7:38723419-38724913:-LIHCEERT_cells_gamma_delta3.3752e-020.1189image
ENSG00000006715.14,VPS41LIHCEAGT_cells_gamma_delta3.3752e-020.1189image
ENSG00000006715.14,VPS41LUADEAGT_cells_CD4_naive6.0245e-03-0.1217image
chr7:38723419-38724913:-LUSCEEREosinophils1.4206e-020.1121image
ENSG00000006715.14,VPS41LUSCEAGEosinophils1.4375e-020.1119image
chr7:38723419-38724913:-MESOEERDendritic_cells_activated5.2911e-060.4817image
ENSG00000006715.14,VPS41MESOEAGDendritic_cells_activated5.2911e-060.4817image
chr7:38723419-38724913:-OVEERMacrophages_M27.9152e-040.1956image
ENSG00000006715.14,VPS41OVEAGMacrophages_M27.9152e-040.1956image
chr7:38723419-38724913:-PAADEERNK_cells_resting9.9138e-04-0.2455image
ENSG00000006715.14,VPS41PAADEAGNK_cells_resting9.9138e-04-0.2455image
chr7:38723419-38724913:-PRADEERMacrophages_M06.5404e-030.1217image
ENSG00000006715.14,VPS41PRADEAGMacrophages_M06.2672e-030.1223image
chr7:38723419-38724913:-READEERDendritic_cells_activated2.1065e-030.3150image
ENSG00000006715.14,VPS41READEAGDendritic_cells_activated2.1065e-030.3150image
chr7:38723419-38724913:-SARCEERPlasma_cells1.0534e-020.1618image
ENSG00000006715.14,VPS41SARCEAGPlasma_cells1.0534e-020.1618image
chr7:38723419-38724913:-SKCMEERT_cells_regulatory_(Tregs)9.1854e-030.1221image
ENSG00000006715.14,VPS41SKCMEAGT_cells_regulatory_(Tregs)9.1854e-030.1221image
chr7:38723419-38724913:-STADEERNK_cells_resting6.3065e-040.1771image
ENSG00000006715.14,VPS41STADEAGNK_cells_resting6.5241e-040.1767image
chr7:38723419-38724913:-TGCTEERB_cells_naive2.2813e-03-0.2441image
ENSG00000006715.14,VPS41TGCTEAGB_cells_naive2.2813e-03-0.2441image
chr7:38723419-38724913:-THCAEERT_cells_CD4_memory_activated1.9996e-030.1373image
ENSG00000006715.14,VPS41THCAEAGT_cells_CD4_memory_activated1.9996e-030.1373image
chr7:38723419-38724913:-THYMEERNK_cells_resting1.0701e-020.2403image
ENSG00000006715.14,VPS41THYMEAGNK_cells_resting1.0701e-020.2403image
ENSG00000006715.14,VPS41UCECEAGEosinophils2.5439e-02-0.1724image
ENSG00000006715.14,VPS41UCSEAGPlasma_cells3.0079e-02-0.2928image


Top

6. Enriched editing regions and immune gene sets for VPS41


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000006715.14,VPS41ACCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG8.4183e-04-0.3751image
ENSG00000006715.14,VPS41BLCAGSVA_HALLMARK_UV_RESPONSE_UPEAG8.4547e-090.2833image
chr7:38723419-38724913:-BLCAGSVA_HALLMARK_UV_RESPONSE_UPEER6.8892e-080.2663image
chr7:38723419-38724913:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.9366e-080.1690image
ENSG00000006715.14,VPS41BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4333e-080.1696image
chr7:38723419-38724913:-CESCGSVA_HALLMARK_UV_RESPONSE_DNEER2.0219e-04-0.2133image
ENSG00000006715.14,VPS41CESCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.0219e-04-0.2133image
chr7:38723419-38724913:-CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.1297e-030.4793image
ENSG00000006715.14,VPS41CHOLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.1297e-030.4793image
ENSG00000006715.14,VPS41COADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG3.7283e-050.2500image
chr7:38723419-38724913:-COADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.4385e-02-0.1513image
ENSG00000006715.14,VPS41DLBCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.3009e-030.4088image
chr7:38723419-38724913:-ESCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.5184e-030.2294image
ENSG00000006715.14,VPS41ESCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG3.4039e-030.2302image
chr7:38723419-38724913:-GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER5.2595e-05-0.3103image
ENSG00000006715.14,VPS41GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG5.2595e-05-0.3103image
chr7:38723419-38724913:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.0444e-030.1266image
ENSG00000006715.14,VPS41HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.0444e-030.1266image
ENSG00000006715.14,VPS41KICHGSVA_HALLMARK_HYPOXIAEAG3.8897e-020.2568image
chr7:38723419-38724913:-KICHGSVA_HALLMARK_HYPOXIAEER3.8897e-020.2568image
ENSG00000006715.14,VPS41KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG3.6023e-05-0.2095image
chr7:38723419-38724913:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER2.2253e-05-0.2149image
ENSG00000006715.14,VPS41KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.4273e-090.3318image
chr7:38723419-38724913:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.4273e-090.3318image
chr7:38723419-38724913:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER3.9771e-16-0.3441image
ENSG00000006715.14,VPS41LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG3.9771e-16-0.3441image
chr7:38723419-38724913:-LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9124e-11-0.3643image
ENSG00000006715.14,VPS41LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.9124e-11-0.3643image
chr7:38723419-38724913:-LUADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.9270e-050.1889image
ENSG00000006715.14,VPS41LUADGSVA_HALLMARK_P53_PATHWAYEAG5.0723e-080.2388image
chr7:38723419-38724913:-LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.3148e-020.0925image
ENSG00000006715.14,VPS41LUSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.3048e-020.0926image
ENSG00000006715.14,VPS41MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3961e-020.2507image
chr7:38723419-38724913:-MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3961e-020.2507image
chr7:38723419-38724913:-OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.7945e-040.2179image
ENSG00000006715.14,VPS41OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7945e-040.2179image
ENSG00000006715.14,VPS41PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.6658e-020.1666image
chr7:38723419-38724913:-PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.6658e-020.1666image
ENSG00000006715.14,VPS41PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.3299e-10-0.4532image
chr7:38723419-38724913:-PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.3299e-10-0.4532image
ENSG00000006715.14,VPS41PRADGSVA_HALLMARK_UV_RESPONSE_DNEAG8.3680e-05-0.1753image
chr7:38723419-38724913:-PRADGSVA_HALLMARK_UV_RESPONSE_DNEER8.4675e-05-0.1752image
chr7:38723419-38724913:-READGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.8748e-030.3183image
ENSG00000006715.14,VPS41READGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.8748e-030.3183image
chr7:38723419-38724913:-SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.1751e-050.2536image
ENSG00000006715.14,VPS41SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.1751e-050.2536image
ENSG00000006715.14,VPS41SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.9841e-07-0.2333image
chr7:38723419-38724913:-SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.9841e-07-0.2333image
chr7:38723419-38724913:-STADGSVA_HALLMARK_GLYCOLYSISEER1.6298e-050.2223image
ENSG00000006715.14,VPS41STADGSVA_HALLMARK_GLYCOLYSISEAG1.8094e-050.2212image
ENSG00000006715.14,VPS41TGCTGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.4492e-050.3416image
chr7:38723419-38724913:-TGCTGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.4492e-050.3416image
chr7:38723419-38724913:-THCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.4640e-03-0.1414image
ENSG00000006715.14,VPS41THCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.4640e-03-0.1414image
chr7:38723419-38724913:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.2509e-08-0.4897image
ENSG00000006715.14,VPS41THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.2509e-08-0.4897image
ENSG00000006715.14,VPS41UCECGSVA_HALLMARK_UV_RESPONSE_UPEAG4.9059e-080.4056image
chr7:38723419-38724913:-UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.5672e-050.3293image
ENSG00000006715.14,VPS41UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.9213e-030.3828image
ENSG00000006715.14,VPS41UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.5696e-050.5044image
chr7:38723419-38724913:-UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5727e-050.5044image


Top

7. Enriched editing regions and drugs for VPS41


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000006715.14,VPS41ACCEHT.1864EAG1.4867e-030.3582image
ENSG00000006715.14,VPS41BLCACCT007093EAG9.8297e-090.2821image
chr7:38723419-38724913:-BLCACCT007093EER9.2552e-080.2638image
chr7:38723419-38724913:-BRCACCT007093EER1.8435e-150.2406image
ENSG00000006715.14,VPS41BRCACCT007093EAG1.5688e-150.2406image
chr7:38723419-38724913:-CESCCCT007093EER1.2565e-020.1442image
ENSG00000006715.14,VPS41CESCCCT007093EAG1.2565e-020.1442image
ENSG00000006715.14,VPS41CHOLCCT007093EAG5.2454e-040.5632image
chr7:38723419-38724913:-CHOLCCT007093EER5.2454e-040.5632image
ENSG00000006715.14,VPS41COADMetforminEAG5.0650e-07-0.3022image
chr7:38723419-38724913:-COADMetforminEER2.0889e-03-0.1897image
ENSG00000006715.14,VPS41DLBCCCT007093EAG3.2026e-030.4299image
chr7:38723419-38724913:-ESCABIRB.0796EER8.0447e-030.2088image
ENSG00000006715.14,VPS41ESCABIRB.0796EAG8.0905e-030.2087image
chr7:38723419-38724913:-GBMBIBW2992EER8.1244e-05-0.3028image
ENSG00000006715.14,VPS41GBMBIBW2992EAG8.1244e-05-0.3028image
chr7:38723419-38724913:-HNSCBMS.536924EER1.1489e-02-0.1166image
ENSG00000006715.14,VPS41HNSCBMS.536924EAG1.1489e-02-0.1166image
chr7:38723419-38724913:-KICHCytarabineEER1.1337e-02-0.3122image
ENSG00000006715.14,VPS41KICHCytarabineEAG1.1337e-02-0.3122image
ENSG00000006715.14,VPS41KIRCCCT007093EAG4.1209e-040.1796image
chr7:38723419-38724913:-KIRCFH535EER3.1287e-030.1506image
chr7:38723419-38724913:-KIRPBAY.61.3606EER1.1890e-090.3492image
ENSG00000006715.14,VPS41KIRPBAY.61.3606EAG1.1890e-090.3492image
chr7:38723419-38724913:-LAMLJNK.9LEER2.5520e-02-0.2279image
ENSG00000006715.14,VPS41LAMLCCT018159EAG3.1489e-020.2186image
chr7:38723419-38724913:-LGGMetforminEER3.1359e-23-0.4136image
ENSG00000006715.14,VPS41LGGMetforminEAG3.1359e-23-0.4136image
ENSG00000006715.14,VPS41LIHCA.770041EAG2.7697e-09-0.3374image
chr7:38723419-38724913:-LIHCA.770041EER2.7697e-09-0.3374image
chr7:38723419-38724913:-LUADGW.441756EER6.4192e-030.1211image
ENSG00000006715.14,VPS41LUADBMS.536924EAG1.3358e-02-0.1102image
chr7:38723419-38724913:-LUSCAUY922EER4.5263e-02-0.0916image
ENSG00000006715.14,VPS41LUSCAUY922EAG4.5133e-02-0.0917image
ENSG00000006715.14,VPS41MESOGefitinibEAG1.1944e-02-0.2781image
chr7:38723419-38724913:-MESOGefitinibEER1.1944e-02-0.2781image
chr7:38723419-38724913:-OVA.770041EER7.8439e-05-0.2294image
ENSG00000006715.14,VPS41OVA.770041EAG7.8439e-05-0.2294image
ENSG00000006715.14,VPS41PAADBMS.708163EAG3.0468e-050.3080image
chr7:38723419-38724913:-PAADBMS.708163EER3.0468e-050.3080image
chr7:38723419-38724913:-PCPGJNJ.26854165EER1.1085e-03-0.2399image
ENSG00000006715.14,VPS41PCPGJNJ.26854165EAG1.1085e-03-0.2399image
ENSG00000006715.14,VPS41PRADAZ628EAG3.9455e-07-0.2269image
chr7:38723419-38724913:-PRADAZ628EER4.4064e-07-0.2260image
chr7:38723419-38724913:-READImatinibEER5.7742e-030.2842image
ENSG00000006715.14,VPS41READImatinibEAG5.7742e-030.2842image
chr7:38723419-38724913:-SARCCGP.082996EER7.8987e-07-0.3069image
ENSG00000006715.14,VPS41SARCCGP.082996EAG7.8987e-07-0.3069image
ENSG00000006715.14,VPS41SKCMBMS.509744EAG2.6404e-11-0.3061image
chr7:38723419-38724913:-SKCMBMS.509744EER2.6404e-11-0.3061image
chr7:38723419-38724913:-STADJNK.Inhibitor.VIIIEER9.9905e-060.2277image
ENSG00000006715.14,VPS41STADJNK.Inhibitor.VIIIEAG1.0038e-050.2276image
chr7:38723419-38724913:-TGCTBMS.509744EER3.2426e-05-0.3282image
ENSG00000006715.14,VPS41TGCTBMS.509744EAG3.2426e-05-0.3282image
chr7:38723419-38724913:-THCACEP.701EER1.4325e-07-0.2320image
ENSG00000006715.14,VPS41THCACEP.701EAG1.4325e-07-0.2320image
chr7:38723419-38724913:-THYMAZD6482EER1.5812e-100.5584image
ENSG00000006715.14,VPS41THYMAZD6482EAG1.5812e-100.5584image
chr7:38723419-38724913:-UCECCCT007093EER5.5453e-050.3085image
ENSG00000006715.14,VPS41UCECCCT007093EAG4.0340e-080.4080image
ENSG00000006715.14,VPS41UCSJNK.Inhibitor.VIIIEAG1.9942e-040.4813image
ENSG00000006715.14,VPS41UVMMG.132EAG6.4980e-08-0.6071image
chr7:38723419-38724913:-UVMMG.132EER6.4680e-08-0.6072image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType